FDA awards Novartis expanded approval for breast cancer therapy
Kisqali, a key targeted therapy for breast cancer from Novartis, until now has been indicated…
Category: Novartis
STAT+: FDA approves Roche’s injectable version of blockbuster multiple sclerosis drug
Swiss pharma giant Roche won approval from the Food and Drug Administration on Friday for…
STAT+: Novartis to spend $200 million in further bid to boost radiopharma manufacturing, market dominance
Novartis is opening a new manufacturing facility in California and expanding an existing production site…
STAT+: U.K. trade group scolds Novo, Novartis, Pfizer and Otsuka for violating industry codes
Four large drugmakers — Novartis, Pfizer, Novo Nordisk, and Otsuka Pharmaceutical — were scolded by…
STAT+: Colorado state board decides a pricey Novartis medicine is unaffordable
A blockbuster arthritis drug from Novartis may face a limit on what Colorado health plans…
STAT+: Will Geron be acquired? The long-short view
This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can…
STAT+: Novartis is flashing warning signs about the fate of its newly acquired myelofibrosis drug
CHICAGO — Something is off about the way Novartis is talking about pelabresib, its newly…
STAT+: Novartis sues Maryland over the role of contract pharmacies in a U.S. drug discount program
Novartis has filed a lawsuit seeking to block a Maryland law that requires the company…
Listen: Controversial brain tissue research, obesity drug sales, and Novartis’ M&A drama
The removal of small amounts of brain tissue from desperately ill patients, done as part…
STAT+: New, serious safety risk related to MorphoSys’ cancer drug complicates, potentially threatens, Novartis acquisition
MorphoSys is dealing with an emerging safety issue related to pelabresib, the experimental treatment for…
STAT+: A looming cancer vaccine test for Gritstone Bio, and pushback about Novartis-MorphoSys
This week, I address pushback I received on my Novartis-MorphoSys column. But first, a preview…
STAT+: Why Novartis is going to walk away from its acquisition of MorphoSys
Novartis said Monday that it intends to buy MorphoSys for just under $3 billion. The…
STAT+: Novartis to buy German biotech MorphoSys for $2.9 billion
Novartis said late Monday it has agreed to buy German biotech MorphoSys and its pipeline…
STAT+: FDA scolds Novartis over a misleading TV ad for a breast cancer treatment
The U.S. Food and Drug Administration scolded Novartis for making false and misleading statements about…
STAT+: Could sickle cell someday be treated not with CRISPR, but with a pill?
Two gene therapies were approved for sickle cell disease last week, but for many researchers…
.jpg)
STAT+: Results on Novartis prostate cancer therapy could expand its use
MADRID — Results presented Monday could expand the use of a Novartis therapy for metastatic…
STAT+: Why Novartis is changing the name of its research labs
Swiss drugmaker Novartis’ research and development hub has a new name — and a new…